July 17, 2023 : Haleon, a global consumer healthcare company, has entered into a licensing agreement with Futura Medical to commercialize MED3000. This agreement marks a significant milestone as MED3000 becomes the first and only clinically proven gel treatment for erectile dysfunction (ED) that can be purchased without a doctor’s prescription in the United States, which is the largest consumer healthcare market worldwide.
Under the agreement, Haleon will take charge of all investments and activities associated with the product’s launch and marketing in the USA. On the other hand, Futura will provide ongoing technical support for developing over-the-counter (OTC) products and opportunities for commercialization.
Globally, approximately one in five men experience ED, with around 22 million men in the USA suffering from this condition, making it the largest ED market in the world. Currently, most ED sufferers in the USA do not seek treatment. MED3000 aims to address the needs of these individuals by offering a safe, effective, and fast-acting treatment option that can be purchased without a prescription.
James Barder, the Chief Executive of Futura Medical, expressed his excitement about the agreement, stating that it represents a significant milestone for the company. Futura recently obtained approval from the US Food and Drug Administration (FDA) for MED3000 as the first OTC topical gel for ED. Barder believes that Haleon, a leading global consumer healthcare company with strong brand-building and marketing capabilities across various channels and its extensive market reach and connections, is the ideal partner to introduce MED3000 to millions of ED sufferers in the USA. In the near future, MED3000 will be available for purchase in US pharmacies without needing a doctor’s prescription.
Prior to this agreement, MED3000 had already received approval as the first pan-European clinically proven topical treatment for ED-available OTC. It is currently accessible in Belgium and the UK.